Mechanisms and Therapy for Cancer Metastasis to the Brain

Federica Franchino, Roberta Rudà, Riccardo Soffietti, Federica Franchino, Roberta Rudà, Riccardo Soffietti

Abstract

Advances in chemotherapy and targeted therapies have improved survival in cancer patients with an increase of the incidence of newly diagnosed brain metastases (BMs). Intracranial metastases are symptomatic in 60-70% of patients. Magnetic resonance imaging (MRI) with gadolinium is more sensitive than computed tomography and advanced neuroimaging techniques have been increasingly used in the detection, treatment planning, and follow-up of BM. Apart from the morphological analysis, the most effective tool for characterizing BM is immunohistochemistry. Molecular alterations not always reflect those of the primary tumor. More sophisticated methods of tumor analysis detecting circulating biomarkers in fluids (liquid biopsy), including circulating DNA, circulating tumor cells, and extracellular vesicles, containing tumor DNA and macromolecules (microRNA), have shown promise regarding tumor treatment response and progression. The choice of therapeutic approaches is guided by prognostic scores (Recursive Partitioning Analysis and diagnostic-specific Graded Prognostic Assessment-DS-GPA). The survival benefit of surgical resection seems limited to the subgroup of patients with controlled systemic disease and good performance status. Leptomeningeal disease (LMD) can be a complication, especially in posterior fossa metastases undergoing a "piecemeal" resection. Radiosurgery of the resection cavity may offer comparable survival and local control as postoperative whole-brain radiotherapy (WBRT). WBRT alone is now the treatment of choice only for patients with single or multiple BMs not amenable to surgery or radiosurgery, or with poor prognostic factors. To reduce the neurocognitive sequelae of WBRT intensity modulated radiotherapy with hippocampal sparing, and pharmacological approaches (memantine and donepezil) have been investigated. In the last decade, a multitude of molecular abnormalities have been discovered. Approximately 33% of patients with non-small cell lung cancer (NSCLC) tumors and epidermal growth factor receptor mutations develop BMs, which are targetable with different generations of tyrosine kinase inhibitors (TKIs: gefitinib, erlotinib, afatinib, icotinib, and osimertinib). Other "druggable" alterations seen in up to 5% of NSCLC patients are the rearrangements of the "anaplastic lymphoma kinase" gene TKI (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib). In human epidermal growth factor receptor 2-positive, breast cancer targeted therapies have been widely used (trastuzumab, trastuzumab-emtansine, lapatinib-capecitabine, and neratinib). Novel targeted and immunotherapeutic agents have also revolutionized the systemic management of melanoma (ipilimumab, nivolumab, pembrolizumab, and BRAF inhibitors dabrafenib and vemurafenib).

Keywords: brain metastases; chemotherapy; neuroimaging; neuropathology; stereotactic radiosurgery; surgery; targeted therapy; whole-brain radiotherapy.

References

    1. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol (2012) 14(9):1171–7.10.1093/neuonc/nos152
    1. Tabouret E, Bauchet L, Carpentier AF. Brain metastases epidemiology and biology. Bull Cancer (2013) 100(1):57–62.10.1684/bdc.2012.1681
    1. Taillibert S, Le Rhun É. Epidemiology of brain metastases. Cancer Radiother (2015) 19(1):3–9.10.1016/j.canrad.2014.11.001
    1. Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. Breast (2016) 25:22–6.10.1016/j.breast.2015.11.006
    1. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov (2015) 5(11):1164–77.10.1158/-15-0369
    1. Saunus JM, Quinn MC, Patch AM, Pearson JV, Bailey PJ, Nones K, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol (2015) 237(3):363–78.10.1002/path.4583
    1. Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, et al. Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov (2015) 5(6):610–21.10.1158/-14-1129
    1. Svokos SA, Salhia B, Toms SA. Molecular biology of brain metastasis. Int J Mol Sci (2014) 15:9519–30.10.3390/ijms15069519
    1. Winkler F. The brain metastatic niche. J Mol Med (2015) 93(11):1213–20.10.1007/s00109-015-1357-0
    1. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 153:865–73.10.1016/S0002-9440(10)65628-3
    1. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev (2009) 28:15–33.10.1007/s10555-008-9169-0
    1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871–90.10.1016/j.cell.2009.11.007
    1. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res (2010) 316:1324–31.10.1016/j.yexcr.2010.02.045
    1. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141:39–51.10.1016/j.cell.2010.03.014
    1. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev (2009) 28:113–27.10.1007/s10555-008-9173-4
    1. Beasley KD, Toms SA. The molecular pathobiology of metastasis to the brain: a review. Neurosurg Clin N Am (2011) 22(1):7–14, v.10.1016/j.nec.2010.08.009
    1. Custódio-Santos T, Videira M, Brito MA. Brain metastasization of breast cancer. Biochim Biophys Acta (2017) 1868(1):132–47.10.1016/j.bbcan.2017.03.004
    1. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis (2011) 28(1):13–25.10.1007/s10585-010-9354-8
    1. Reid H, Rahul J. The role of the neural niche in brain metastasis. Clin Exp Metastasis (2017) 34:369–76.10.1007/s10585-017-9857-7
    1. Kim SW, Choi HJ, Lee HJ, He J, Wu Q, Langley RR, et al. Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro Oncol (2014) 16(12):1585–98.10.1093/neuonc/nou128
    1. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother (2012) 61(6):789–801.10.1007/s00262-011-1137-9
    1. Termini J, Neman J, Jandial R. Role of the neural niche in brain metastatic cancer. Cancer Res (2014) 74(15):4011–5.10.1158/0008-5472.CAN-14-1226
    1. Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A (2014) 111(3):984–9.10.1073/pnas.1322098111
    1. Kralik SF, Kamer AP, Ho CY. Diagnostic imaging of intracranial metastasis. Curr Probl Cancer (2015) 39(2):99–112.10.1016/j.currproblcancer.2015.03.003
    1. Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of neuro-Oncology (EANO). Neuro Oncol (2017) 19(2):162–74.10.1093/neuonc/now241
    1. Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol (1990) 11(4):785–91.
    1. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol (1999) 44(3):275–81.10.1023/A:1006308808769
    1. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar Ø, et al. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol (2010) 51(3):316–25.10.3109/02841850903482901
    1. Sparacia G, Gadde JA, Iaia A, Sparacia B, Midiri M. Usefulness of quantitative peritumoural perfusion and proton spectroscopic magnetic resonance imaging evaluation in differentiating brain gliomas from solitary brain metastases. Neuroradiol J (2016) 29(3):160–7.10.1177/1971400916638358
    1. Duygulu G, Ovali GY, Calli C, Kitis O, Yünten N, Akalin T, et al. Intracerebral metastasis showing restricted diffusion: correlation with histopathological findings. Eur J Radiol (2010) 74(1):117–20.10.1016/j.ejrad.2009.03.004
    1. Chiang IC, Kuo YT, Lu CY, Yeung KW, Lin WC, Sheu FO, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology (2004) 46(8):619–27.10.1007/s00234-004-1246-7
    1. Xu XX, Li B, Yang HF, Du Y, Li Y, Wang WX, et al. Can diffusion-weighted imaging be used to differentiate brain abscess from other ring-enhancing brain lesions? A meta-analysis. Clin Radiol (2014) 69:909–15.10.1016/j.crad.2014.04.012
    1. Tan Y, Wang X-C, Zhang H, Wang J, Qin JB, Wu XF, et al. Differentiation of high-grade-astrocytomas from solitary-brain-metastases: comparing diffusion kurtosis imaging and diffusion tensor imaging. Eur J Radiol (2015) 84:2618–24.10.1016/j.ejrad.2015.10.007
    1. Jiang R, Du FZ, He C, Gu M, Ke ZW, Li JH. The value of diffusion tensor imaging in differentiating high-grade gliomas from brain metastases: a systematic review and meta-analysis. PLoS One (2014) 9(11):e112550.10.1371/journal.pone.0112550
    1. Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol (2006) 5(11):937–48.10.1016/S1474-4422(06)70597-X
    1. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging (2002) 29(2):176–82.10.1007/s00259-001-0690-4
    1. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2013) 54(2):229–35.10.2967/jnumed.112.109603
    1. Le Chevalier T, Smith FP, Caille P, Constans JP, Rouesse JG. Sites of primary malignancies in patients presenting with cerebral metastases. Arch Intern Med (1985) 149(5):880–2.
    1. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med (1989) 149(5):1076–80.10.1001/archinte.1989.00390050066013
    1. Van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry (1996) 61(3):321–3.10.1136/jnnp.61.3.321
    1. Klee B, Law I, Højgaard L, Kosteljanetz M. Detection of unknown primary tumors in patients with cerebral metastases using whole-body 18F-fluorodeoxyglucose positron emission tomography. Eur J Neurol (2002) 9(6):657–62.10.1046/j.1468-1331.2002.00467.x
    1. Weller D. Screening, resilience, patient navigation and information needs – key areas in cancer control. Eur J Cancer Care (Engl) (2016) 25(1):3–5.10.1111/ecc.12439
    1. Rudà R, Borgognone M, Benech F, Vasario E, Soffietti R. Brain metastases from unknown primary tumor: a prospective study. J Neurol (2001) 248(5):394–8.10.1007/s004150170180
    1. Bekaert L, Emery E, Levallet G, Lechapt-Zalcman E. Histopathologic diagnosis of brain metastases: current trends in management and future considerations. Brain Tumor Pathol (2017) 34:8–19.10.1007/s10014-016-0275-3
    1. Becher MW, Abel TW, Thompson RC, Weaver KD, Davis LE. Immunohistochemical analysis of metastatic neoplasms of the central nervous system. J Neuropathol Exp Neurol (2006) 65(10):935–44.10.1097/01.jnen.0000235124.82805.2b
    1. Jin J, Zhou X, Liang X, Huang R, Chu Z, Jiang J, et al. Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center. J Cancer Res Clin Oncol (2013) 139(3):403–8.10.1007/s00432-012-1344-6
    1. Pekmezci M, Perry A. Neuropathology of brain metastases. Surg Neurol Int (2013) 4(Suppl 4):245–55.10.4103/2152-7806.111302
    1. Kim MY, Go H, Koh J, Lee K, Lee K, Min HS, et al. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin. Histopathology (2014) 65(2):195–206.10.1111/his.12383
    1. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol (2012) 123(2):205–22.10.1007/s00401-011-0933-9
    1. Kawaguchi KR, Lu FI, Kaplan R, Liu YF, Chadwick P, Chen Z, et al. In search of the ideal immunopanel to distinguish metastatic mammary carcinoma from primary lung carcinoma: a tissue microarray study of 207 cases. Appl Immunohistochem Mol Morphol (2014) 22(4):266–74.10.1097/PAI.0b013e318297cc0b
    1. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev (2012) 38(6):708–14.10.1016/j.ctrv.2011.11.006
    1. Lee HS, Kim WH, Kwak Y, Koh J, Bae JM, Kim KM, et al. Molecular testing for gastrointestinal cancer. J Pathol Transl Med (2017) 51(2):103–21.10.4132/jptm.2017.01.24
    1. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med (2011) 154(1):37–49.10.7326/0003-4819-154-1-201101040-00006
    1. Sorich MJ, Wise MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol (2015) 26(1):13–21.10.1093/annonc/mdu378
    1. Bahrami A, Hesari A, Khazaei M, Hassanian SM, Ferns GA, Avan A. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. J Cell Physiol (2018) 233(3):2162–9.10.1002/jcp.26041
    1. Cohen R, Svrcek M, Dreyer C, Cervera P, Duval A, Pocard M, et al. New therapeutic opportunities based on DNA mismatch repair and BRAF status in metastatic colorectal cancer. Curr Oncol Rep (2016) 18(3):18.10.1007/s11912-016-0504-2
    1. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer (2015) 51(5):587–94.10.1016/j.ejca.2015.01.054
    1. Cohen R, Cervera P, Svrcek M, Pellat A, Dreyer C, de Gramont A, et al. BRAF-mutated colorectal cancer: what is the optimal strategy for treatment? Curr Treat Options Oncol (2017) 18(2):9.10.1007/s11864-017-0453-5
    1. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 117(20):4623–32.10.1002/cncr.26086
    1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 8(5):381–5.10.1513/pats.201107-042ST
    1. Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer Amst Neth (2014) 83(1):83–9.10.1016/j.lungcan.2013.10.004
    1. Payne LS, Huang PH. Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J Thorac Oncol (2014) 9(6):900–4.10.1097/JTO.0000000000000164
    1. Sekine A, Satoh H. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Med Oncol (2017) 34(7):121.10.1007/s12032-017-0978-2
    1. Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol (2013) 111(1):1–10.10.1007/s11060-012-0990-5
    1. Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J (2011) 37(3):624–31.10.1183/09031936.00195609
    1. Shonka N, Venur VA, Ahluwalia MS. Targeted treatment of brainmetastases. Curr Neurol Neurosci Rep (2017) 17(4):37.10.1007/s11910-017-0741-2
    1. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol (2011) 29(15):443–5.10.1200/JCO.2010.34.1313
    1. Bergethon K, Shaw AT, Ou SHI, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 30(8):863–70.10.1200/JCO.2011.35.6345
    1. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxta membrane domain in primary resected lung cancers. J Thorac Oncol (2009) 4(1):5–11.10.1097/JTO.0b013e3181913e0e
    1. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 12(5):349–61.10.1038/nrc3218
    1. Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol (2014) 27(6):689–96.10.1097/WCO.0000000000000146
    1. Timmer M, Werner JM, Röhn G, Ortmann M, Blau T, Cramer C, et al. Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res (2017) 37(9):4859–65.10.21873/anticanres.11894
    1. Wang J, Bettegowda C. Applications of DNA-based liquid biopsy for central nervous system neoplasm. J Mol Diagn (2017) 19(1):24–34.10.1016/j.jmoldx.2016.08.007
    1. Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol (2017) 19(9):1248–54.10.1093/neuonc/nox066
    1. Polivka J, Jr, Pesta M, Janku F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn (2015) 15(12):1631–44.10.1586/14737159.2015.1110021
    1. Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the Association for Molecular Pathology. J Mol Diagn (2015) 17:209–24.10.1016/j.jmoldx.2015.02.001
    1. Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol (2016) 34(20):2404–15.10.1200/JCO.2016.66.6487
    1. Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, et al. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genom Data (2014) 2:60–2.10.1016/j.gdata.2014.04.003
    1. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun (2015) 6:8839.10.1038/ncomms9839
    1. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, et al. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res (2013) 73(23):7134–43.10.1158/0008-5472.CAN-13-2051
    1. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, et al. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat (2015) 154(2):339–49.10.1007/s10549-015-3610-1
    1. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol (2017) 28(Suppl 4):iv84–99.10.1093/annonc/mdx221
    1. Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, et al. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn (2014) 16(5):558–63.10.1016/j.jmoldx.2014.04.008
    1. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys (1997) 37:745–51.10.1016/S0360-3016(96)00619-0
    1. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 43(4):795–803.10.1016/S0360-3016(98)00442-8
    1. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys (2008) 70:510–4.10.1016/j.ijrobp.2007.06.074
    1. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2010) 77(3):655–61.10.1016/j.ijrobp.2009.08.025
    1. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol (2017) 3(6):827–31.10.1001/jamaoncol.2016.3834
    1. Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys (2017) 99(4):812–6.10.1016/j.ijrobp.2017.06.2454
    1. Venur VA, Ahluwalia MS. Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol (2015) 4(2):18.10.3978/j.issn.2304-3865.2015.06.01
    1. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 322(8):494–500.10.1056/NEJM199002223220802
    1. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol (1993) 33(6):583–90.10.1002/ana.410330605
    1. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer (1996) 78(7):1470–6.10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>;2-X
    1. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol (2006) 24(8):1289–94.10.1200/JCO.2005.04.6235
    1. Patel AJ, Suki D, Hatiboglu MA, Rao VY, Fox BD, Sawaya R. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. J Neurosurg (2015) 122(5):1132–43.10.3171/2014.9.JNS13939
    1. Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg (2008) 108(2):248–57.10.3171/JNS/2008/108/2/0248
    1. Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol (2003) 61(1):73–80.10.1023/A:1021262218151
    1. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, et al. Treatment of single brain metastasis with resection, intracavitary carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res (2007) 13(12):3637–41.10.1158/1078-0432.CCR-06-2095
    1. Schwarz SB, Thon N, Nikolajek K, Niyazi M, Tonn JC, Belka C, et al. Iodine-125 brachytherapy for brain tumours-a review. Radiat Oncol (2012) 7:30.10.1186/1748-717X-7-30
    1. Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJ, Debougnoux-Huppertz RM, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 66(1):187–94.10.1016/j.ijrobp.2006.03.050
    1. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int Radiat Oncol Biol Phys (2000) 47(2):291–8.10.1016/S0360-3016(99)00507-6
    1. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys (2005) 63(1):37–46.10.1016/j.ijrobp.2005.05.023
    1. Manon R, O’Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol (2005) 23(34):8870–6.10.1200/JCO.2005.01.8747
    1. Fuentes S, Delsanti C, Metellus P, Peragut JC, Grisoli F, Regis J. Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery (2006) 58(1):37–42.10.1227/01.NEU.0000190655.95669.5C
    1. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet (2004) 363(9422):1665–72.10.1016/S0140-6736(04)16250-8
    1. Rades D, Kueter JD, Veninga T, Gliemroth J, Schild SE. Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis. Eur J Cancer (2009) 45(3):400–4.10.1016/j.ejca.2008.10.033
    1. Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, et al. Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg (2009) 111(3):439–48.10.3171/2008.11.JNS08984
    1. Menoux I, Armspach JP, Noël G, Antoni D. Imaging methods used in the differential diagnosis between brain tumour relapse and radiation necrosis after stereotactic radiosurgery of brain metastases: literature review. Cancer Radiother (2016) 20(8):837–45.10.1016/j.canrad.2016.07.098
    1. Menoux I, Noël G, Namer I, Antoni D. PET scan and NMR spectroscopy for the differential diagnosis between brain radiation necrosis and tumour recurrence after stereotactic irradiation of brain metastases: place in the decision tree. Cancer Radiother (2017) 21(5):389–97.10.1016/j.canrad.2017.03.003
    1. Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N, et al. Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys (2003) 56(3):793–800.10.1016/S0360-3016(03)00014-2
    1. Minniti G, D’Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol (2014) 117(2):295–301.10.1007/s11060-014-1388-3
    1. Eaton BR, LaRiviere MJ, Kim S, Prabhu RS, Patel K, Kandula S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol (2015) 123(1):103–11.10.1007/s11060-015-1767-4
    1. O’Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O’Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys (2003) 55(5):1169–76.10.1016/S0360-3016(02)04379-1
    1. Muacevic A, Kreth FW, Horstmann GA, Schmid-Elsaesser R, Wowra B, Steiger HJ, et al. Surgery and radiotherapy compared with gamma-knife radiosurgery in the treatment of solitary brain metastases of small diameter. J Neurosurg (1999) 91(1):35–43.10.3171/jns.1999.91.1.0035
    1. Hart MG, Grant R, Walker M, Dickinson H. Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev (2005) 25(1):CD003292.10.1002/14651858.CD003292.pub2
    1. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA (1998) 280(17):1485–9.10.1001/jama.280.17.1485
    1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA (2006) 295(21):2483–91.10.1001/jama.295.21.2483
    1. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2011) 29(2):134–41.10.1200/JCO.2010.30.1655
    1. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2015) 91(4):710–7.10.1016/j.ijrobp.2014.10.024
    1. Aoyama H, Tago M, Shirato H, Japanese Radiation Oncology Study Group 99-1 (JROSG 99-1) Investigators . Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol (2015) 1(4):457–64.10.1001/jamaoncol.2015.1145
    1. Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, et al. Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the north central cancer treatment group N0574 (Alliance) randomized controlled trial. Int J Radiat Oncol Biol Phys (2017) 99(5):1173–8.10.1016/j.ijrobp.2017.07.045
    1. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 10(11):1037–44.10.1016/S1470-2045(09)70263-3
    1. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA (2016) 316(4):401–9.10.1001/jama.2016.9839
    1. Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol (2013) 31(1):65–72.10.1200/JCO.2011.41.0639
    1. Lamba N, Muskens IS, DiRisio AC, Meijer L, Briceno V, Edrees H, et al. Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol (2017) 12(1):106.10.1186/s13014-017-0840-x
    1. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol (2017) 18(8):1049–60.10.1016/S1470-2045(17)30441-2
    1. Scheitler-Ring K, Ge B, Petroski G, Biedermann G, Litofsky NS. Radiosurgery to the postoperative tumor bed for metastatic carcinoma versus whole brain radiation after surgery. Cureus (2016) 8(11):e885.10.7759/cureus.885
    1. Rao G, Ahmed S, Hess K, Mahajan A. Postoperative stereotactic radiosurgery vs observation for completely resected brainmetastases: results of a prospective randomized study. Neurosurgery (2016) 63(Suppl 1):184.10.1227/01.neu.0000489784.83922.17
    1. Atalar B, Modlin LA, Choi CY, Adler JR, Gibbs IC, Chang SD, et al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys (2013) 87:713–8.10.1016/j.ijrobp.2013.07.034
    1. Johnson MD, Avkshtol V, Baschnagel AM, Meyer K, Ye H, Grills IS, et al. Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2016) 94:537–43.10.1016/j.ijrobp.2015.11.022
    1. Ojerholm E, Lee JY, Thawani JP, Miller D, O’Rourke DM, Dorsey JF, et al. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg (2014) 121(Suppl):75–83.10.3171/2014.6.GKS14708
    1. Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, et al. Single-fraction versus multifraction (3x9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys (2016) 95(4):1142–8.10.1016/j.ijrobp.2016.03.013
    1. Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol (2015) 125(1):149–56.10.1007/s11060-015-1881-3
    1. Patel KR, Burri SH, Boselli D, Symanowski JT, Asher AL, Sumrall A, et al. Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis. J Neurooncol (2017) 131(3):611–8.10.1007/s11060-016-2334-3
    1. Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol (2017) 19(2):281–8.10.1093/neuonc/now149
    1. Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K. Bevacizumab as treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuo Oncol (2013) 15(9):1257–63.10.1093/neuonc/not085
    1. Hsieh J, Elson P, Otvos B, Rose J, Loftus C, Rahmathulla G, et al. Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases. Neurosurgery (2015) 76:411–20.10.1227/NEU.0000000000000626
    1. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol (2007) 25(10):1260–6.10.1200/JCO.2006.09.2536
    1. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer (2012) 118(9):2486–93.10.1002/cncr.26515
    1. Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys (2009) 73(4):1069–76.10.1016/j.ijrobp.2008.05.068
    1. Scott C, Suh J, Stea B, Nabid A, Hackman J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol (2007) 30(6):580–7.10.1097/COC.0b013e3180653c0d
    1. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet (2016) 388(10055):2004–14.10.1016/S0140-6736(16)30825-X
    1. Patel KR, Prabhu RS, Kandula S, Oliver DE, Kim S, Hadjipanayis C, et al. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol (2014) 120:657–63.10.1007/s11060-014-1601-4
    1. Trifiletti DM, Lee CC, Schlesinger D, Larner JM, Xu Z, Sheehan JP. Leukoencephalopathy after stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys (2015) 93:870–8.10.1016/j.ijrobp.2015.07.2280
    1. Kotecha R, Damico N, Miller JA, Suh JH, Murphy ES, Reddy CA, et al. Three or more courses of stereotactic radiosurgery for patients with multiply recurrent brain metastases. Neurosurgery (2017) 80(6):871–9.10.1093/neuros/nyw147
    1. Tofilon P, Fike J. The radioresponse of the central nervous system: a dynamic process. Radiat Res (2000) 153:357–70.10.1667/0033-7587(2000)153[0357:TROTCN];2
    1. Monaco EA, Faraji AH, Berkowitz O, Parry PV, Hadelsberg U, Kano H, et al. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer (2013) 19(1):226–32.10.1002/cncr.27504
    1. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 39(6):789–96.10.1212/WNL.39.6.789
    1. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol (2013) 15(10):1429–37.10.1093/neuonc/not114
    1. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol (2015) 33(15):1653–9.10.1200/JCO.2014.58.4508
    1. Dye NB, Gondi V, Mehta MP. Strategies for preservation of memory function in patients with brain metastases. Chin Clin Oncol (2015) 4(2):24.10.3978/j.issn.2304-3865.2015.05.05
    1. Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol (2003) 16(2):12–34.10.1097/00019052-200304000-00002
    1. Gibson E, Monje M. Effect of cancer therapy on neural stem cells: implications for cognitive function. Curr Opin Oncol (2012) 24(6):672–8.10.1097/CCO.0b013e3283571a8e
    1. Zhao R, Kong W, Shang J, Zhe H, Wang YY. Hippocampal-sparing whole-brain radiotherapy for lung cancer. Clin Lung Cancer (2017) 18(2):127–31.10.1016/j.cllc.2016.09.007
    1. Ghia A, Tomé WA, Thomas S, Cannon G, Khuntia D, Kuo JS, et al. Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys (2007) 68(4):971–7.10.1016/j.ijrobp.2007.02.016
    1. Marsh JC, Herskovic AM, Gielda BT, Hughes FF, Hoeppner T, Turian J, et al. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys (2010) 76(2):504–12.10.1016/j.ijrobp.2009.02.038
    1. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol (2014) 32(34):3810–6.10.1200/JCO.2014.57.2909
    1. Suh JH. Hippocampal-avoidance whole-brain radiation therapy: a new standard for patients with brain metastases? J Clin Oncol (2014) 32(34):3789–91.10.1200/JCO.2014.58.4367
    1. Vecil GG, Suki D, Maldaun MV, Lang FF, Sawaya R. Resection of brain metastases previously treated with stereotactic radiosurgery. J Neurosurg (2005) 102(2):209–15.10.3171/jns.2005.102.2.0209
    1. Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH. Reoperation for recurrent metastatic brain tumors. J Neurosurg (1995) 83(4):600–4.10.3171/jns.1995.83.4.0600
    1. Arbit E, Wroński M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer (1995) 76(5):765–73.10.1002/1097-0142(19950901)76:5<765::AID-CNCR2820760509>;2-E
    1. Chao ST, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Neyman G, et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer (2008) 113(8):2198–204.10.1002/cncr.23821
    1. Caballero JA, Sneed PK, Lamborn KR, Ma L, Denduluri S, Nakamura JL, et al. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys (2012) 83(1):303–9.10.1016/j.ijrobp.2011.06.1987
    1. Kurtz G, Zadeh G, Gingras-Hill G, Millar BA, Laperriere NJ, Bernstein M, et al. Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection. Int J Radiat Oncol Biol Phys (2014) 88(1):137–42.10.1016/j.ijrobp.2013.10.003
    1. Lucas JT, Jr, Colmer HG, IV, White L, Fitzgerald N, Isom S, Bourland JD, et al. Competing risk analysis of neurologic versus nonneurologic death in patients undergoing radiosurgical salvage after whole-brain radiation therapy failure: who actually dies of their brain metastases? Int J Radiat Oncol Biol Phys (2015) 92(5):1008–15.10.1016/j.ijrobp.2015.04.032
    1. Hsu F, Kouhestani P, Nguyen S, Cheung A, McKenzie M, Ma R, et al. Population-based outcomes of boost versus salvage radiosurgery for brain metastases after whole brain radiotherapy. Radiother Oncol (2013) 108(1):128–31.10.1016/j.radonc.2013.04.025
    1. Kim DH, Schultheiss TE, Radany EH, Badie B, Pezner RD. Clinical outcomes of patients treated with a second course of stereotactic radiosurgery for locally or regionally recurrent brain metastases after prior stereotactic radiosurgery. J Neurooncol (2013) 115(1):37–43.10.1007/s11060-013-1191-6
    1. Chen JC, Petrovich Z, Giannotta SL, Yu C, Apuzzo ML. Radiosurgical salvage therapy for patients presenting with recurrence of metastatic disease to the brain. Neurosurgery (2000) 46(4):860–6.10.1227/00006123-200004000-00017
    1. Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg (2011) 114(3):792–800.10.3171/2010.8.JNS10461
    1. Shultz DB, Modlin LA, Jayachandran P, Von Eyben R, Gibbs IC, Choi CYH, et al. Repeat courses of stereotactic radiosurgery (SRS), deferring whole-brain irradiation, for new brain metastases after initial SRS. Int J Radiat Oncol Biol Phys (2015) 92(5):993–9.10.1016/j.ijrobp.2015.04.036
    1. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, et al. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD Anderson Cancer Center experience. Clin Cancer Res (2011) 17(12):4110–8.10.1158/1078-0432.CCR-10-3095
    1. Venur VA, Ahluwalia MS. Novel terapeutica agents in the management of brain metastases. Curr Opin Oncol (2017) 29(5):395–9.10.1097/CCO.0000000000000393
    1. Soffietti R, Rudà R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol (2008) 20(6):676–84.10.1097/CCO.0b013e32831186fe
    1. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2010) 96(1):71–83.10.1007/s11060-009-0062-7
    1. Zhu W, Zhou L, Qian JQ, Qiu TZ, Shu YQ, Liu P. Temozolomide for treatment of brain metastases: a review of 21 clinical trials. World J Clin Oncol (2014) 5:19–27.10.5306/wjco.v5.i1.19
    1. Preusser M, Berghoff AS, Schadendorf D, Lin NU, Stupp R. Brain metastasis: opportunity for drug development? Curr Opin Neurol (2012) 25(6):786–94.10.1097/WCO.0b013e328359320d
    1. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, et al. Updates in the management of brain metastases. Neuro Oncol (2016) 18(8):1043–65.10.1093/neuonc/now127
    1. Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol (2014) 16(1):276.10.1007/s11940-013-0276-z
    1. Lin J, Jandial R, Nesbit A, Badie B, Chen M. Current and emerging treatments for brain metastases. Oncology (2015) 29(4):250–7.
    1. Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol (2012) 24(6):679–86.10.1097/CCO.0b013e3283571a1c
    1. Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AK, Vlahovic G. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology (2016) 5(7):e1172153.10.1080/2162402X.2016.1172153
    1. Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med (2016) 4:S9.10.21037/atm.2016.09.40
    1. Leal T, Chang JE, Mehta M, Robins HI. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev (2011) 7:319–27.10.2174/157339411797642597
    1. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer (2004) 45(Suppl 2):S253–7.10.1016/j.lungcan.2004.07.967
    1. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res (2016) 22(20):5130–40.10.1158/1078-0432.CCR-16-0399
    1. Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. Onco Targets Ther (2014) 7:2075–84.10.2147/OTT.S67586
    1. Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer (2013) 80(3):242–8.10.1016/j.lungcan.2013.02.004
    1. Broniscer A, Panetta JC, O’Shaughnessy M, Fraga C, Bai F, Krasin MJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res (2007) 13(5):1511–5.10.1158/1078-0432.CCR-06-2372
    1. Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer (2013) 14(2):188–93.10.1016/j.cllc.2012.06.004
    1. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol (2015) 16(2):141–51.10.1016/S1470-2045(14)71173-8
    1. Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol (2016) 11(3):380–90.10.1016/j.jtho.2015.11.014
    1. Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent afatinib and whole-brain radiotherapy in exon 19-del-EGFR mutant lung adenocarcinoma: a case report and mini review of the literature. Front Oncol (2017) 10(7):88.10.3389/fonc.2017.00088
    1. Yamanaka Y, Sekine A, Kato T, Yamakawa H, Ikeda S, Baba T, et al. Afatinib therapy for brain metastases aggravated by a reduction in the dose of Erlotinib due to the development of hepatotoxicity. Intern Med (2017) 56(21):2895–8.10.2169/internalmedicine.8638-16
    1. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res (2012) 18(4):938–44.10.1158/1078-0432.CCR-11-2529
    1. Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev (2014) 40(6):716–22.10.1016/j.ctrv.2014.03.005
    1. Jiang T, Min W, Li Y, Yue Z, Wu C, Zhou C. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med (2016) 5(6):1055–65.10.1002/cam4.673
    1. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 31(7):895–902.10.1200/JCO.2011.40.1174
    1. Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst (2014) 106(7):dju151.10.1093/jnci/dju151
    1. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320. Int J Radiat Oncol Biol Phys (2013) 85(5):1312–8.10.1016/j.ijrobp.2012.11.042
    1. Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol (2017) 28(10):2443–50.10.1093/annonc/mdx359
    1. Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med (2017) 5(9):707–16.10.1016/S2213-2600(17)30262-X
    1. Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med (2016) 8(368):368ra172.10.1126/scitranslmed.aag0976
    1. Tan CS, Cho BC, Soo RA. Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs? Lung Cancer (2017) 108:29–37.10.1016/j.lungcan.2017.02.012
    1. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer (2013) 80(3):278–83.10.1016/j.lungcan.2013.01.019
    1. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol (2015) 33(17):1881–8.10.1200/JCO.2014.59.0539
    1. Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK. Treatment of brain metastases in the modern genomic era. Pharmacol Ther (2016) 170:64–72.10.1016/j.pharmthera.2016.10.011
    1. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs (2010) 11(12):1477–90.
    1. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (2017) 389(10072):917–29.10.1016/S0140-6736(17)30123-X
    1. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet (2017) 390(10089):29–39.10.1016/S0140-6736(17)30565-2
    1. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol (2017) 35(22):2490–8.10.1200/JCO.2016.71.5904
    1. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol (2017) 18(12):1590–9.10.1016/S1470-2045(17)30680-0
    1. Hochmair MJ, Schwab S, Prosch H. Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient. Anticancer Drugs (2017) 28(8):928–30.10.1097/CAD.0000000000000525
    1. Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol (2015) 122(2):409–17.10.1007/s11060-015-1733-1
    1. Chabot P, Hsia TC, Ryu JS, Gorbunova V, Belda-Iniesta C, Ball D, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol (2017) 131(1):105–15.10.1007/s11060-016-2275-x
    1. Hochart A, Leblond P, Le Bourhis X, Meignan S, Tulasne D. MET receptor inhibition: hope against resistance to targeted therapies? Bull Cancer (2017) 104(2):157–66.10.1016/j.bulcan.2016.10.014
    1. Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol (2014) 89(2):284–99.10.1016/j.critrevonc.2013.11.006
    1. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther (2012) 11(10):2149–57.10.1158/1535-7163.MCT-12-0195
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med (2015) 373(2):123–35.10.1056/NEJMoa1504627
    1. Dudnik E, Yust-Katz S, Nechushtan H, Goldstein DA, Zer A, Flex D, et al. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer (2016) 98:114–7.10.1016/j.lungcan.2016.05.031
    1. Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, et al. P2.36: nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets): track: immunotherapy. J Thorac Oncol (2016) 11(10S):S238–9.10.1016/j.jtho.2016.08.107
    1. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or nonsmall-cell lung cancer and untreated brain metastases: early analysis of a nonrandomised, open-label, phase 2 trial. Lancet Oncol (2016) 17:976–83.10.1016/S1470-2045(16)30053-5
    1. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer (2006) 107(6):1348–54.10.1002/cncr.22127
    1. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol (2006) 78(3):261.10.1007/s11060-006-9155-8
    1. Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev (2013) 39(7):720–7.10.1016/j.ctrv.2013.01.006
    1. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis (2015) 32(7):729–37.10.1007/s10585-015-9740-3
    1. De Vries CL, Linn SC, Brandsma D. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. J Neurooncol (2016) 127(2):401–3.10.1007/s11060-015-2045-1
    1. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol (2014) 25(6):1116–21.10.1093/annonc/mdu133
    1. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 372(8):724–34.10.1056/NEJMoa1413513
    1. Petrelli F, Ghidini M, Lonati V, Tomasello G, Borgonovo K, Ghilardi M, et al. The efficacy ofl apatinib and capecitabinein HER-2 positive breast cancerwith brain metastases: a systematic review and pooled analysis. Eur J Cancer (2017) 84:141–8.10.1016/j.ejca.2017.07.024
    1. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 26(12):1993–9.10.1200/JCO.2007.12.3588
    1. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol (2013) 14(1):64–71.10.1016/S1470-2045(12)70432-1
    1. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational breast cancer research consortium (TBCRC) 022: a phase II of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol (2016) 34(9):945–52.10.1200/JCO.2015.63.0343
    1. Kümler I, Tuxen MK, Nielsen D. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Trat Rev (2014) 40(2):259–70.10.1016/j.ctrv.2013.09.002
    1. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, et al. Bevacizumab preconditioning follone by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res (2015) 21(8):1851–8.10.1158/1078-0432.CCR-14-2075
    1. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol (2014) 25(12):2357–62.10.1093/annonc/mdu456
    1. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (2013) 381(9861):125–32.10.1016/S0140-6736(12)61134-9
    1. Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 4:33.10.1186/s40164-015-0028-8
    1. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2011) 117:1687–96.10.1002/cncr.25634
    1. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 113(8):2139–45.10.1002/cncr.23805
    1. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 16:375–84.10.1016/S1470-2045(15)70076-8
    1. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 386:444–51.10.1016/S0140-6736(15)60898-4
    1. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol (2017) 28(7):1631–9.10.1093/annonc/mdx176
    1. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 13(11):1087–95.10.1016/S1470-2045(12)70431-X
    1. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 13(5):459–65.10.1016/S1470-2045(12)70090-6
    1. McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol (2017) 28(3):634–41.10.1093/annonc/mdw641
    1. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol (2015) 33:1889–94.10.1200/JCO.2014.56.2736
    1. Davey RJ, Westhuizen AV, Bowden NA. Metastatic melanoma treatment: combining old and new therapies. Crit Rev Oncol Hematol (2016) 98:242–53.10.1016/j.critrevonc.2015.11.011
    1. Pardoll DE. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev (2012) 12:252–64.10.1038/nrc3239
    1. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517–26.10.1056/NEJMoa1104621
    1. Hodi FS, O Day SH, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711–23.10.1056/NEJMoa1003466
    1. Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res (2016) 4:744–54.10.1158/2326-6066.CIR-15-0156
    1. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol (2015) 26(4):798–803.10.1093/annonc/mdu577
    1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrozilumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134–44.10.1056/NEJMoa1305133
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443–54.10.1056/NEJMoa1200690
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2015) 372:320–30.10.1056/NEJMoa1412082
    1. Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH, Jr, et al. Overall survival in patients with advanced melanoma who received Nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol (2017) 36(4):383–90.10.1200/JCO.2016.71.8023
    1. Carlino MS, Long GV. Ipilimumab combined with Nivolumab: a standard of care for the treatment of advanced melanoma? Clin Cancer Res (2016) 22(16):3992–8.10.1158/1078-0432.CCR-15-2944
    1. Spain L, Schmid T, Gore M, Larkin J. Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. Eur J Cancer (2017) 75:243–4.10.1016/j.ejca.2016.12.040
    1. Barker A, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res (2013) 1(2):92–8.10.1158/2326-6066.CIR-13-0082
    1. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2013) 85(2):293–5.10.1016/j.ijrobp.2012.03.017
    1. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 117:227–33.10.3171/2012.5.JNS111929
    1. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 92(2):368–75.10.1016/j.ijrobp.2015.01.004
    1. Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer (2016) 122:3051–8.10.1002/cncr.30138
    1. Shen C, Lin DD, Redmond KJ, Link K, Kummerlowe M, Douglass J, et al. Imaging and clinical profile following concurrent stereotactic radiation and immune therapy for melanoma brain metastases: preliminary results. Int J Radiat Oncol Biol Phys (2016) 96:E134.10.1016/j.ijrobp.2016.06.927
    1. Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol (2016) 27:434–41.10.1093/annonc/mdv622
    1. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2015) 372(1):30–9.10.1056/NEJMoa1412690
    1. Ramanujam S, Schadendorf D, Long GV. Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol (2015) 4(2):25.10.3978/j.issn.2304-3865.2015.06.06
    1. Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist (2015) 20(7):789–97.10.1634/theoncologist.2014-0012
    1. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer (2014) 50(3):611–21.10.1016/j.ejca.2013.11.002
    1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 367:1694–703.10.1056/NEJMoa1210093
    1. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol (2016) 8(1):48–56.10.1177/1758834015616934
    1. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 371:1867–76.10.1056/NEJMoa1408868
    1. Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol (2015) 122(1):121–6.10.1007/s11060-014-1685-x
    1. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol (2013) 113:411–6.10.1007/s11060-013-1127-1
    1. Postow MA, Carvajal RD. Therapeutic implications of KIT in melanoma. Cancer J (2012) 18(2):137–41.10.1097/PPO.0b013e31824b2404
    1. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 26(12):2046–51.10.1200/JCO.2007.14.0707
    1. Rudà R, Franchino F, Soffietti R. Treatment of brain metastasis: current status and future directions. Curr Opin Oncol (2016) 28(6):502–10.10.1097/CCO.0000000000000326
    1. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brainmetastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2010) 96(1):103–14.10.1007/s11060-009-0057-4
    1. Weston J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev (2015) 4(3):CD007286.10.1002/14651858.CD007286.pub2
    1. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2010) 96(1):97–102.10.1007/s11060-009-0056-5
    1. Lobos-Urbina D, Kittsteiner-Manubens L, Peña J. Is primary prevention with antiepileptic drugs effective in brain tumors or brainmetastases? Medwave (2017) 17(Suppl1):e6871.10.5867/medwave.2017.6871
    1. Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol (2010) 98(1):109–16.10.1007/s11060-009-0069-0
    1. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol (2015) 33(6):654–6.10.1200/JCO.2014.59.7351
    1. Kreuziger LB. Balancing bleeding in brain metastases. Blood (2015) 126(4):432–3.10.1182/blood-2015-06-648089
    1. Hunter BD, Minichiello T, Bent S. Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review. J Thromb Thrombolysis (2017) 44(3):392–8.10.1007/s11239-017-1536-7
    1. Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med (2018) 378(7):615–24.10.1056/NEJMoa1711948
    1. Brown PD, Asher AL, Ballman KV, Farace E, Cerhan JH, Keith Anderson S, et al. NCCTG N0574 (alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol (2015) 33(Suppl):abstrLBA4.10.1200/jco.2015.33.18_suppl.lba4
    1. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med (2017) 5(5):435–44.10.1016/S2213-2600(17)30129-7
    1. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol (2004) 15(7):1042–7.10.1093/annonc/mdh276
    1. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol (2014) 15(10):1119–28.10.1016/S1470-2045(14)70362-6
    1. Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 370(13):1189–97.10.1056/NEJMoa1311107
    1. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol (2016) 34:2866–73.10.1200/JCO.2015.65.5936
    1. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol (2016) 17(12):1683–96.10.1016/S1470-2045(16)30392-8
    1. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol (2017) 35(12):1288–96.10.1200/JCO.2016.70.3223
    1. Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol (2016) 17(7):984–93.10.1016/S1470-2045(16)30146-2
    1. Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUXbreast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol (2015) 16(16):1700–10.10.1016/s1470-2045(15)00373-3
    1. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol (2017) 40(5):444–50.10.1097/COC.0000000000000199
    1. Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 21(6):530–4.10.1097/CMR.0b013e32834d3d88
    1. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 2:899–906.10.1002/cam4.140
    1. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res (2013) 23:191–5.10.1097/CMR.0b013e32835f3d90
    1. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (2017) 390(10105):1853–62.10.1016/S0140-6736(17)31601-X
    1. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer (2017) 116(12):1558–63.10.1038/bjc.2017.142

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi